Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)

Most patients with malignant ovarian germ cell tumors (MOGTCs) have a very good prognosis and chemotherapy provides curative treatment; however, patients with yolk sac tumors (OYSTs) have a significantly worse prognosis. OYSTs are rare tumors and promising results are expected with the use of specif...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-01, Vol.13 (2), p.220
Main Authors: Hodroj, Khalil, Stevovic, Aleksandra, Attignon, Valery, Ferraioli, Domenico, Meeus, Pierre, Croce, Sabrina, Chopin, Nicolas, Rossi, Lea, Floquet, Anne, Rousset-Jablonski, Christine, Tredan, Olivier, Guyon, Frédéric, Treilleux, Isabelle, Rannou, Corinne, Morfouace, Marie, Ray-Coquard, Isabelle
Format: Article
Language:English
Subjects:
Cancer therapies
Cell cycle
Cell growth
Chemotherapy
Gene deletion
Gene expression
Kinases
Medical prognosis
Microsatellite instability
Mutation
Oophorectomy
Ovaries
Patients
Platinum
Prognosis
Tumors
Yolk
Yolk sac
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Most patients with malignant ovarian germ cell tumors (MOGTCs) have a very good prognosis and chemotherapy provides curative treatment; however, patients with yolk sac tumors (OYSTs) have a significantly worse prognosis. OYSTs are rare tumors and promising results are expected with the use of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens. We initiated a project in collaboration with EORTC SPECTA, to explore the molecular characteristics of OYSTs. The pilot project used retrospective samples from ten OYST relapsed and disease-free patients. Each patient had a molecular analysis performed with FoundationOne CDx describing the following variables according to the Foundation Medicine Incorporation (FMI): alteration type (SNV, deletion), actionable gene alteration, therapies approved in EU (for patient's tumor type and other tumor types), tumor mutational burden (TMB), and microsatellite instability (MSI) status. A total of 10 patients with OYST diagnosed between 2007 and 2017 had a molecular analysis. A molecular alteration was identified in four patients (40%). A subset of three patients (33.3% of all patients) harbored targetable oncogenic mutations in , , . Two patients at relapse harbored a targetable mutation. This retrospective study identifies clinically relevant molecular alterations for all relapsed patients with molecular analysis. Dedicated studies are needed to demonstrate the efficacy of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens and to explore the potential relationship of a molecular alteration and patient outcome.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13020220